Objective: To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy. Methods: A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, n = 40) or the observation group (OG, n = 40). While the OG received capecitabine and docetaxel supplemented by an ultrasound-mediated drug delivery strategy intended to enhance intratumoral absorption, the CG received cisplatin and docetaxel. The groups were compared in terms of clinical response, immunological function, quality of life (FACT-B), incidence of adverse events, and serum tumor markers. Results: Compared with the CG, the OG showed a considerably greater response rate (RR) and disease control rate ( p 0.05). Following therapy, tumor markers CA125 and CA153 reduced in both cohorts ( p < 0.05), with the OG showing larger reductions ( p < 0.05). Conclusions: Capecitabine and docetaxel administered via ultrasound improve therapeutic efficacy in advanced TNBC, lessen immune suppression brought on by treatment, improve quality of life, and support a positive safety profile while encouraging higher decreases in tumor marker expression. These results demonstrate the potential therapeutic benefit of using ultrasound-based medication delivery techniques into TNBC systemic therapy.
Liu et al. (Fri,) studied this question.